Evidence map›Paper›PMID 42446938›Full record

ArticleNucleic acids research2026

Engineering aptamer dimers (apdimers) for optimization of synthetic riboswitches.

Vera Hedwig, Elisabeth Müller, Stephanie Ketterer, Isabel Lang, Matthias Klugmann, Jörg S Hartig

Abstract read
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vera HedwigDepartment of Chemistry, University of Konstanz, Konstanz 78457, Germany.ORCID 0009-0008-0193-8697
Elisabeth MüllerDepartment of Chemistry, University of Konstanz, Konstanz 78457, Germany.ORCID 0009-0001-8956-5942
Stephanie KettererResearch Beyond Borders, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss 88400, Germany.
Isabel LangResearch Beyond Borders, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss 88400, Germany.
Matthias KlugmannResearch Beyond Borders, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss 88400, Germany.
Jörg S HartigDepartment of Chemistry, University of Konstanz, Konstanz 78457, Germany.ORCID 0000-0001-6601-7217

Funding

University of Konstanz
6 · The paper itself

Abstract

Riboswitches are compact RNA-based regulatory elements capable of modulating gene expression in response to small molecules, without the need for additional proteins. Various synthetic riboswitches have been engineered using in vitro-generated tetracycline and theophylline aptamers. However, many of these constructs exhibit suboptimal switching efficiency and background expression. Moreover, efforts to enhance their performance often involve time-consuming and costly screening processes. Here we report that artificial riboswitches can be efficiently optimized by engineering fusion aptamers that contain two binding pockets (apdimers). Following this rational approach, we generated cooperativity between both binding pockets, resulting in the improved performance of splicing-based and ribozyme-based synthetic riboswitches. We finally combined optimized tetracycline switches, yielding dynamic ranges exceeding 1000-fold with minimal background expression in the OFF state. In addition, we show that the optimized tetracycline riboswitches can be used to efficiently induce AAV-mediated transgene expression in mice. The presented strategy offers a straightforward and effective approach for the optimization of existing synthetic riboswitches and the design of novel riboswitches.

Indexed as

Aptamers, NucleotideGenetic EngineeringRiboswitchAnimalsBinding SitesDimerizationMiceNucleic Acid ConformationRNA, CatalyticTetracyclineTheophyllineAptamers, NucleotideRiboswitchRNA, CatalyticTetracyclineTheophylline

Identifiers

PMID42446938
PMCPMC13367181

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.